Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

598
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
598
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

1.1K
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

943
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
943
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.9K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

1.8K
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.8K
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

764
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
764

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial.

JAMA cardiology·2017
Same author

Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 Trial.

Journal of the American Heart Association·2017
Same author

Accelerometer-Measured Daily Activity in Heart Failure With Preserved Ejection Fraction: Clinical Correlates and Association With Standard Heart Failure Severity Indices.

Circulation. Heart failure·2017
Same author

Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).

Circulation. Cardiovascular quality and outcomes·2017
Same author

Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial.

JAMA·2017
Same author

INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved Ejection Fraction): Rationale and Design.

Circulation. Heart failure·2017

相关实验视频

Updated: May 5, 2026

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat
04:30

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat

Published on: February 4, 2021

3.4K

动脉狭窄症的病理生理基础和治疗:JACC的最新研究

Milind Y Desai1, Eugene Braunwald2

  • 1Miller Family Heart, Vascular & Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA.

Journal of the American College of Cardiology
|August 27, 2025
PubMed
概括

动脉狭窄 (CAVS) 是一种常见的心脏病,目前没有治疗方法可以减缓其进展. 新研究强调需要更好的标志物和治疗方法来控制与年龄相关的疾病.

关键词:
大动脉缩症管理层病理生理学

更多相关视频

Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro
05:47

Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro

Published on: May 10, 2021

4.2K
Isolation of Human Primary Valve Cells for In vitro Disease Modeling
07:31

Isolation of Human Primary Valve Cells for In vitro Disease Modeling

Published on: April 16, 2021

2.8K

相关实验视频

Last Updated: May 5, 2026

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat
04:30

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat

Published on: February 4, 2021

3.4K
Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro
05:47

Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro

Published on: May 10, 2021

4.2K
Isolation of Human Primary Valve Cells for In vitro Disease Modeling
07:31

Isolation of Human Primary Valve Cells for In vitro Disease Modeling

Published on: April 16, 2021

2.8K

科学领域:

  • 心脏病学
  • 血管生物学
  • 生物医学工程

背景情况:

  • 动脉狭窄 (CAVS) 是成年人中最常见的门疾病,随着年龄的增长而增加.
  • 目前对CAVS的治疗侧重于门置换,缺乏预防或延缓疾病进展的选择.
  • 基本的CAVS进展包括化,氧化应激,炎症,脂蛋白沉积和骨质信号.

研究的目的:

  • 提供CAVS病变和进展的全面审查.
  • 强调对CAVS的创新医疗治疗的需求.
  • 探索新兴的治疗策略和CAVS的先进诊断/监测方法.

主要方法:

  • 对CAVS的发病,进展和治疗的文献综述.
  • 讨论疾病进展的传统和新兴标志物.
  • 探索新的治疗方法和疗效测量技术.

主要成果:

  • CAVS的进展是多因素的,涉及化,炎症和信号通路.
  • 传统的标志物可能不反映早期可修改的疾病阶段.
  • 作为监测CAVS进展的敏感标志物, 大动脉的化显得有前途.

结论:

  • 迫切需要有效的医学疗法来预防或延缓CAVS的进展.
  • 需要先进的标志物来监测早期疾病和治疗疗效.
  • 目前正在研究针对CAVS底层机制的创新治疗方法.